您当前的位置：
首页 >
文章列表页 >
Cost-effectiveness analysis of fluzoparib monotherapy versus combination with apatinib in the treatment of germline BRCA1/2-mutated HER2-negative metastatic breast cancer
更新时间：2026-07-28

    • Cost-effectiveness analysis of fluzoparib monotherapy versus combination with apatinib in the treatment of germline BRCA1/2-mutated HER2-negative metastatic breast cancer

    • ZHONGGUO YAOFANG   Vol. 37, Issue 14, Pages: 1862-1867(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.14.11    

      CLC： R956

    • Received：08 January 2026，

      Revised：2026-07-13，

      Accepted：13 July 2026，

      Online First：24 July 2026，

      Published：30 July 2026

    移动端阅览

  • WANG Liyuan,ZHANG Lingli,HOU Yanhong.Cost-effectiveness analysis of fluzoparib monotherapy versus combination with apatinib in the treatment of germline BRCA1/2-mutated HER2-negative metastatic breast cancer[J].ZHONGGUO YAOFANG,2026,37(14):1862-1867. DOI： 10.6039/j.issn.1001-0408.2026.14.11.

  •  
  •  

0

Views

1

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Pharmacoeconomic evaluation of culmerciclib combined with fulvestrant in the second-line treatment of HR+/HER2－ locally advanced or metastatic breast cancer
Cost-utility analysis of anlotinib combined with penpulimab in first-line treatment of unresectable hepatocellular carcinoma
Cost-utility analysis of rezivertinib versus gefitinib as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer
白蛋白结合型紫杉醇与溶剂型紫杉醇治疗转移性乳腺癌的最小成本分析
阿帕替尼联合全身化疗用于胃肠胰神经内分泌肿瘤肝转移的临床观察

Related Author

LIU Guoqiang
LIU Ziyi
WANG Yue
ZHANG Ranran
ZHANG Yuxi
LI Congxin
GAO Shengnan
LIU Ran

Related Institution

Dept. of Pharmacy， Hebei Medical University Third Hospital
School of Graduate， Hebei Medical University
Hebei Society for Integrated Drug and Health Technology Assessment
Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital
Hebei Provincial Society for Integrated Drug and Health Technology Assessment
0